Stay updated on Depemokimab in Severe Asthma Clinical Trial
Sign up to get notified when there's something new on the Depemokimab in Severe Asthma Clinical Trial page.

Latest updates to the Depemokimab in Severe Asthma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s revision number has been updated from v3.5.3 to v3.5.4, reflecting a small update to the page’s documentation/versioning.SummaryDifference0.0%

- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe page’s footer was updated to reflect a newer ClinicalTrials.gov revision version (v3.5.3). A previously listed journal publication citation was removed from the Publications section.SummaryDifference0.0%

- Check56 days agoChange DetectedIQVIA Pty Ltd was added to the Collaborators and Investigators section and Iqvia Pty Ltd was removed, reflecting capitalization normalization of the organization name.SummaryDifference0.0%

- Check63 days agoChange DetectedPublications section updated with a new reference: Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.SummaryDifference0.0%

- Check71 days agoChange DetectedA new publication citation has been added: Heffler E et al., Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis. Front Allergy, 2026.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision: v3.5.0 has been added to the page. The previous revision entry, v3.4.3, has been removed.SummaryDifference0.0%

Stay in the know with updates to Depemokimab in Severe Asthma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Depemokimab in Severe Asthma Clinical Trial page.